Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Alison Hirukawa, Harvey W. Smith, Dongmei Zuo, Catherine R. Dufour, Paul Savage, Nicholas Bertos, Radia M. Johnson, Tung Bui, Guillaume Bourque, Mark Basik, Vincent Giguère, Morag Park, William J. Muller
Format: article
Langue:EN
Publié: Nature Portfolio 2018
Sujets:
Q
Accès en ligne:https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!